These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22647638)

  • 41. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease].
    Kull E; Beau P
    Gastroenterol Clin Biol; 2002 Apr; 26(4):367-71. PubMed ID: 12070412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
    Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME
    Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy.
    Hall B; Holleran G; Chin JL; Smith S; Ryan B; Mahmud N; McNamara D
    J Crohns Colitis; 2014 Dec; 8(12):1601-9. PubMed ID: 25257546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
    Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment.
    Hazlewood GS; Pokharel G; Deardon R; Marshall DA; Bombardier C; Tomlinson G; Ma C; Seow CH; Panaccione R; Kaplan GG
    PLoS One; 2020; 15(1):e0227635. PubMed ID: 31945089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute lymphoid leukemia in a Crohn's disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids.
    Cesarini M; Vernia P; Angelucci E
    Inflamm Bowel Dis; 2010 Mar; 16(3):371-2. PubMed ID: 19637388
    [No Abstract]   [Full Text] [Related]  

  • 53. Metastatic vulval Crohn's disease and infliximab: a case report.
    Tritton SM; Whyte L; Fischer G
    J Reprod Med; 2009 Jan; 54(1):41-4. PubMed ID: 19263879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
    Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
    Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
    Panés J; López-Sanromán A; Bermejo F; García-Sánchez V; Esteve M; Torres Y; Domènech E; Piqueras M; Gomez-García M; Gutiérrez A; Taxonera C; Sans M;
    Gastroenterology; 2013 Oct; 145(4):766-74.e1. PubMed ID: 23770132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sjögren's syndrome associated with Crohn's disease successfully treated with adalimumab.
    Tursi A
    J Crohns Colitis; 2012 Mar; 6(2):263. PubMed ID: 22325185
    [No Abstract]   [Full Text] [Related]  

  • 59. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
    Gupta A; Pendyala P; Arora P; Sitrin MD
    J Clin Gastroenterol; 2011 Mar; 45(3):e30-3. PubMed ID: 20975576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic lupus erythematosus and Crohn's disease: an uncommon association of two autoimmune diseases.
    Sanchez-Burson J; Garcia-Porrua C; Melguizo MI; Gonzalez-Gay MA
    Clin Exp Rheumatol; 2004; 22(1):133. PubMed ID: 15005019
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.